Literature DB >> 899716

Clinical, neurophysiological and morphological findings in Eaton Lambert syndrome.

K G Henriksson, O Nilsson, I Rosén, H H Schiller.   

Abstract

Two patients with maysthenic syndrome apparently not associated with carcinoma were studied in detail with repetitive stimulation of motor nerves, single fibre electromyography and histology. One patient showed signs of widespread autonomic dysfunction and the other patient had multifocal CNS symptoms of unclear etiology. Both cases showed a marked improvement with guanidine treatment which could be documented by the electrophysiological investigations. Due to severe adverse effects of the guanidine treatment on kidney, pancreatic and bone marrow functions the drug had to be withdrawn. Edrophonium given intravenously caused a marked and longlasting improvement of the muscle weakness and of the neurophysiological parameters. The mechanism of action is suggested to be different from that seen in myasthenia gravis. Single fibre electromyography showed a marked increase of neuromuscular jitter and blockings which decreased with increasing innervation frequency. The morphological study showed a selective affection of type II (fast twitch) fibres, a finding which is suggested to be secondary to an impaired neuromuscular transmission in the type II motor units.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 899716     DOI: 10.1111/j.1600-0404.1977.tb01417.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

1.  4-aminopyridine--a new drug tested in the treatment of Eaton-Lambert syndrome.

Authors:  H Lundh; O Nilsson; I Rosén
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-11       Impact factor: 10.154

Review 2.  Lambert-Eaton myasthenic syndrome.

Authors:  U Seneviratne; R de Silva
Journal:  Postgrad Med J       Date:  1999-09       Impact factor: 2.401

3.  Autonomic dysfunction in Lambert-Eaton myasthenic syndrome.

Authors:  S A Waterman
Journal:  Clin Auton Res       Date:  2001-06       Impact factor: 4.435

4.  Cancer-associated myasthenic (Eaton-Lambert) syndrome: distribution of abnormality and effect of treatment.

Authors:  D A Ingram; G R Davis; M S Schwartz; M Traub; A C Newland; M Swash
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

Review 5.  Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.

Authors:  Michael T Flink; William D Atchison
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

6.  Cephalic tetanus studied with single fibre EMG.

Authors:  J M Fernandez; M Ferrandiz; L Larrea; R Ramio; M Boada
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-09       Impact factor: 10.154

Review 7.  3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.

Authors:  J Molgó; J M Guglielmi
Journal:  Pflugers Arch       Date:  1996       Impact factor: 3.657

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.